COPENHAGEN—Shares in Novo Nordisk rose more than 3 percent on Wednesday after the Danish drug developer delivered a better-than-expected earnings outlook for 2022 despite missing fourth-quarter operating profit expectations. The world’s largest diabetes drug developer expects to generate sales growth of between 6 percent and 10 percent in local currencies in 2022 and deliver operating…